AllianceBernstein’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-40,692
Closed -$200K 3096
2016
Q4
$200K Hold
40,692
﹤0.01% 2894
2016
Q3
$202K Hold
40,692
﹤0.01% 2843
2016
Q2
$207K Buy
40,692
+2,800
+7% +$15.1K ﹤0.01% 2796
2016
Q1
$216K Hold
37,892
﹤0.01% 2697
2015
Q4
$393K Sell
37,892
-1,400
-4% -$19K ﹤0.01% 2532
2015
Q3
$726K Sell
39,292
-1,400
-3% -$27K ﹤0.01% 2326
2015
Q2
$792K Buy
40,692
+2,600
+7% +$46K ﹤0.01% 2400
2015
Q1
$670K Buy
38,092
+5,300
+16% +$89K ﹤0.01% 2372
2014
Q4
$524K Sell
32,792
-200
-0.6% -$2.68K ﹤0.01% 2503
2014
Q3
$415K Buy
32,992
+200
+0.6% +$2.85K ﹤0.01% 2559
2014
Q2
$512K Buy
32,792
+271
+0.8% +$3.98K ﹤0.01% 2509
2014
Q1
$427K Sell
32,521
-1,484
-4% -$23.2K ﹤0.01% 2488
2013
Q4
$547K Sell
34,005
-11,918
-26% -$190K ﹤0.01% 2404
2013
Q3
$764K Sell
45,923
-6,654
-13% -$98.4K ﹤0.01% 2269
2013
Q2
$529K Buy
+52,577
New +$552K ﹤0.01% 2461

Other funds holding OSIR

AllianceBernstein's OSIR Position: Q1 2017 in Review

AllianceBernstein sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2017, closing a stake of 40,692 shares — an estimated $200K sold.

AllianceBernstein first reported a position in OSIR in Q2 2013 and held it in 15 quarters. The position peaked at $792K in Q2 2015. 11 funds tracked by Wall St. Rank hold OSIR as of Q1 2017.

  • AllianceBernstein reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • AllianceBernstein sold 40,692 Osiris Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $200K.
  • AllianceBernstein first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
  • AllianceBernstein's Osiris Therapeutics, Inc. Common Stock position peaked at $792K in Q2 2015.
  • 11 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2017.

Based on AllianceBernstein's 13F filing for Q1 2017, filed 11 May 2017.